LAT010
/ Latticon Antibody Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 06, 2024
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
(clinicaltrials.gov)
- P1/2 | N=150 | Recruiting | Sponsor: Latticon Antibody Therapeutics, Inc | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Oncology • Solid Tumor • CD4 • CD8
February 26, 2024
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
(clinicaltrials.gov)
- P1/2 | N=150 | Not yet recruiting | Sponsor: Latticon Antibody Therapeutics, Inc
Metastases • New P1/2 trial • Oncology • Solid Tumor • CD4 • CD8
1 to 2
Of
2
Go to page
1